Long non-coding RNA CCAT2 as a potential serum biomarker for diagnosis and prognosis of multiple myeloma

Long non-coding RNA CCAT2 as a potential serum biomarker for diagnosis and prognosis of multiple myeloma
复制标题

长非编码RNA CCAT2作为多发性骨髓瘤诊断和预后的潜在血清生物标志物

DOI:
10.1007/s00277-020-04161-9
复制
发表时间:
2020-06
期刊:
Ann Hematol
影响因子:
--
通讯作者:
Ju S
Ju S
中科院分区:
其他
文献类型:
--
作者:
Xu H;Yin Q;Shen X;Ju S

文献摘要

参考文献

相似文献

对长链非编码RNA(lncRNA)的认识不断增加,表明它们可用作循环肿瘤标志物。此外,大量证据表明lncRNA在肿瘤诊断和预后中具有重要作用。lncRNA CCAT 2在多种肿瘤中表现出致癌作用,但其在多发性骨髓瘤(MM)中的血清表达水平及临床意义尚待进一步探讨。在我们的研究中,通过使用定量实时聚合酶链反应(qRT-PCR),lncRNA CCAT 2的表达在MM患者的血清和骨髓中上调。MM患者血清中CCAT 2的高表达水平与国际评分系统(ISS)分期、肾功能不全、血清β2-微球蛋白(β2-MG)浓度和轻链(κ和λ)浓度相关。血清中CCAT 2的曲线下面积(AUC)为0.899。其敏感性和特异性分别为85.80%和83%。此外,CCAT 2、伊加、HGB和β2-MG的组合显著提高了MM诊断灵敏度和AUC。在此,我们目前的研究表明,血清循环CCAT 2可能作为一个潜在的肿瘤标志物MM的诊断和预后。
Increasing knowledge of long non-coding RNAs (lncRNAs) has shown that they can be used as circulating tumor markers. Also, considerable evidences have revealed that lncRNAs have important roles in tumor diagnosis and prognosis. The lncRNA CCAT2 has manifested its carcinogenic effect in a variety of tumors, but the serum expression level and clinical value in multiple myeloma (MM) remain to be explored. In our study, the expression of lncRNA CCAT2 is upregulated in the serum and bone marrow of MM patients by using quantitative real-time polymerase chain reaction (qRT-PCR). The high expression level of CCAT2 in the serum of MM patients correlated with International Scoring System (ISS) stages, renal dysfunction, serum β2-microglobulin (β2-MG) concentration, and light chain (κ and λ) concentrations. Area under the curve (AUC) of CCAT2 in serum is 0.899. Besides, the sensitivity and specificity were 85.80% and 83%, respectively. Furthermore, combination of CCAT2, IgA, HGB, and β2-MG significantly improved the MM diagnostic sensitivity and AUC. Here, our present investigation indicates that serum circulating CCAT2 may serve as a potential tumor marker for diagnosis and prognosis of MM.
通过LNA Gapmer ASO吸毒LNCRNA MALAT1抑制蛋白酶体亚基的基因表达,并触发抗多膜骨髓瘤活性。
DOI: 10.1038/s41375-018-0067-3
发表时间: 2018-09
期刊: Leukemia
影响因子: 11.4
作者:
Amodio N;Stamato MA;Juli G;Morelli E;Fulciniti M;Manzoni M;Taiana E;Agnelli L;Cantafio MEG;Romeo E;Raimondi L;Caracciolo D;Zuccalà V;Rossi M;Neri A;Munshi NC;Tagliaferri P;Tassone P
通讯作者: Tassone P
DOI: 10.1038/s41375-018-0104-2
发表时间: 2018-10
期刊: Leukemia
影响因子: 11.4
作者:
Hu Y;Lin J;Fang H;Fang J;Li C;Chen W;Liu S;Ondrejka S;Gong Z;Reu F;Maciejewski J;Yi Q;Zhao JJ
通讯作者: Zhao JJ
DOI: 10.3816/clm.2008.n.021
发表时间: 2008-06-01
期刊: CLINICAL LYMPHOMA & MYELOMA
影响因子: --
作者:
Benetatos, Leonidas;Dasoula, Aggeliki;Bourantas, Konstantinos L.
通讯作者: Bourantas, Konstantinos L.
DOI: 10.1111/ejh.12908
发表时间: 2017-09-01
影响因子: 3.1
作者:
Sedlarikova, Lenka;Gromesova, Barbora;Sevcikova, Sabina
通讯作者: Sevcikova, Sabina
DOI: 10.1038/cddis.2017.358
发表时间: 2017-08-10
影响因子: 9
作者:
Yang N;Chen J;Zhang H;Wang X;Yao H;Peng Y;Zhang W
通讯作者: Zhang W